GS
GSAC.US GelStat Corp
- Market cap
- USD 1.50M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is GSAC.US undervalued?
Graham numberThe Graham number of GelStat Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GelStat Corp fundamental analysis
No fundamental analysis for GelStat Corp yet.
GelStat Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GelStat Corp
GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter (OTC) and other non-prescription consumer health care products to commercial, industrial, and government customers. It offers control automation systems, encrypted control devices, variable base encryption compression, and specialized technologies specialized technologies to aid law enforcement and other security personnel. Chemical Recycling. GelStat …
Full company profileGelStat Corp financial statements
GelStat Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 15.9K | 1.31M | - | 201K | 3.95K | 7.02K | 2.33K | 150K | 350K | 268K |
| Gross Profit | 3.50K | 222K | - | 200K | -131K | -173K | -408K | 131K | 234K | -128K |
| Operating Income | -410K | -1.30M | -8.84K | 175K | -178K | -313K | -602K | -166K | -281K | -242K |
| EBITDA | -408K | -1.24M | -8.84K | 181K | 2.00K | -206K | -519K | -150K | -251K | -212K |
| Net Income | -407K | -1.30M | -8.84K | 175K | -178K | -475K | -761K | -210K | -373K | -327K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 3.12M | 7.05M | 75.00 | 100K | 140K | 182K | 18.8K | 186K | 171K | 270K |
| Total Liabilities | 210K | 1.37M | 20.2K | 320K | 344K | 511K | 724K | 964K | 1.22M | 1.52M |
| Shareholders' Equity | 2.91M | 5.68M | -20.1K | -220K | -204K | -329K | -705K | -778K | -1.05M | -1.25M |
| Cash & Short-term Investments | 95.1K | 96.7K | 75.00 | 1.00K | 767.00 | 67.1K | 1.73K | 25.3K | 8.83K | 5.39K |
| Total Debt | - | 17.2K | - | 2.00K | 197K | 256K | 363K | 584K | 665K | 853K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -145K | -239K | -275K | -172K | -85.2K | -205K | -172K | -106K | -57.2K | -62.8K |
| Capital Expenditure | 9.52K | 4.58K | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 1.00 | 3.00 | 4.00 |
| Free Cash Flow | -155K | -244K | -275K | -172K | -85.2K | -205K | -172K | -106K | -57.2K | -62.8K |
| Ratios | ||||||||||
| ROE | -14.0% | -22.9% | - | - | - | - | - | - | - | - |
| ROA | -13.1% | -18.4% | -11,785.3% | 175.0% | -126.8% | -260.9% | -4,041.4% | -113.0% | -218.3% | -121.1% |
| Net Profit Margin | -2,563.3% | -98.9% | - | 87.1% | -4,502.2% | -6,764.5% | -32,618.9% | -140.5% | -106.7% | -121.9% |
| Debt to Equity | - | 0.00x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GelStat Corp dividends
GelStat Corp has not paid dividends in the last 10 fiscal years.
Last stock split: 3:2 on Sep 1, 2004.
Who owns GelStat Corp
- Insiders 9.52%
- Institutions 0.00%
- Public & others 90.48%
- Shares outstanding 3.74B
- Free float 1.18B
GelStat Corp company profile
- Company name
- GelStat Corp
- Ticker
- GSAC.US
- Exchange
- USA Stocks
- Listed since
- Apr 23, 1993
- Sector
- Technology
- Industry
- Pharmaceuticals
- Employees
- 2
- Fiscal year end
- December
- Address
- 333 SE 2nd Avenue, Miami, FL, United States, 33131
- Phone
- 772-212-1368
- Website
- gelstat.com
About GelStat Corp
GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter (OTC) and other non-prescription consumer health care products to commercial, industrial, and government customers. It offers control automation systems, encrypted control devices, variable base encryption compression, and specialized technologies specialized technologies to aid law enforcement and other security personnel. Chemical Recycling. GelStat Corporation was founded in 2002 and is headquartered in Miami, Florida.
GelStat Corp management
3- Mr. Javier G. AcostaCEO & Director
- Mr. Charles F. TarzianChief Marketing Advisor · born 1957
- Dr. Roger K. Cady M.D.Chief Medical Advisor